What is Zacks Research’s Estimate for VRTX Q3 Earnings?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Analysts at Zacks Research increased their Q3 2025 EPS estimates for Vertex Pharmaceuticals in a note issued to investors on Tuesday, December 24th. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will post earnings per share of $4.01 for the quarter, up from their prior estimate of $3.99. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.83) per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.67 EPS.

Several other research analysts have also commented on VRTX. Oppenheimer lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 19th. Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $500.00 to $550.00 in a report on Monday, December 9th. StockNews.com cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. HC Wainwright decreased their price target on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating for the company in a report on Friday, December 20th. Finally, BMO Capital Markets lowered their price objective on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a research report on Friday, December 20th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $494.04.

Vertex Pharmaceuticals Stock Down 0.5 %

NASDAQ:VRTX opened at $408.76 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The company has a market capitalization of $105.27 billion, a price-to-earnings ratio of -205.41 and a beta of 0.36. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88. The stock has a 50-day simple moving average of $462.47 and a 200 day simple moving average of $472.74.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. increased its position in Vertex Pharmaceuticals by 5.6% during the third quarter. Principal Financial Group Inc. now owns 410,359 shares of the pharmaceutical company’s stock worth $190,850,000 after buying an additional 21,649 shares during the last quarter. Lord Abbett & CO. LLC raised its stake in shares of Vertex Pharmaceuticals by 10.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 3,279 shares of the pharmaceutical company’s stock valued at $1,525,000 after acquiring an additional 300 shares in the last quarter. Oddo BHF Asset Management Sas acquired a new stake in Vertex Pharmaceuticals in the 3rd quarter worth approximately $7,912,000. American Trust bought a new stake in Vertex Pharmaceuticals during the third quarter worth approximately $680,000. Finally, Tri Ri Asset Management Corp acquired a new position in Vertex Pharmaceuticals during the third quarter valued at approximately $8,726,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.